,i #aaith ,,congress #b;d ,session ,h4 ,r4 #hhij ,,in ,,the ,,house ,,of ,,representatives ,may #ai1 #bjbf,mr4 ,dunn of ,florida introduced the following bill2 which was referred to the ,committee on ,energy and ,commerce1 and in addition to the ,committee on ,ways and ,means1 for a period to be subsequently determined by the ,speaker1 in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned ,a ,,bill ,to amend the ,public ,health ,services ,act1 commonly referred to as the ,clinical ,laboratory ,improvement ,amendments or ,,clia1 with respect to laboratory developed tests1 and for other purposes4 #a4 ,short title ,this ,act may be cited as the ,enhancing ,clinical ,laboratory ,innovation and ,access ,act of #bjbf or the ,enhancing ,,clia ,act of #bjbf4 #b4 ,enhanced regulation of laboratory developed tests 7a7 ,amendments to the public health services act1 commonly referred to as the clinical laboratory improvement amendments or clia ,section #cec of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #bfc;a7 is amended-- 7#a7 by striking subsection 7a7 and inserting3 7a7 ,scope of authority2 definitions 7#a7 ,scope of authority ,laboratory operations shall be regulated by the ,secretary under this section and not under the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cja et4 seq474 7#b7 ,definitions ,in this section3 7,a7 ,analytical validity ,the term analytical validity means1 with respect to an examination or procedure performed by a laboratory1 the ability of the examination or procedure to provide information that is accurate and reliable with respect to the identification1 measurement1 detection1 or calculation of the target analyte in a specimen1 within a reportable range4 7,b7 ,applicable standard ,the term applicable standard means-- 7i7 for a laboratory developed test for clinical use1 that the test has a reasonable assurance of analytical and clinical validity2 and 7ii7 for a laboratory developed test for investigational use1 that the test has a reasonable assurance of analytical validity4 7,c7 ,clinical use ,the term clinical use-- 7i7 means that an examination or procedure is used for the purpose of providing information for the diagnosis1 prognosis1 identification1 monitoring1 screening1 prevention1 or treatment of any disease or impairment of1 or the assessment of the health of1 human beings2 and 7ii7 does not include-- 7,i7 investigational use2 7,,ii7 research use2 or 7,,iii7 forensic use4 7,d7 ,clinical validity ,the term clinical validity means1 with respect to an examination or procedure performed by a laboratory1 the ability of the examination or procedure to provide information that is accurate and reliable for its stated clinical purpose4 7,e7 ,digital laboratory data ,the term digital laboratory data-- 7i7 means digital data derived from a laboratory examination or procedure performed by a laboratory on materials taken or derived from the human body1 including-- 7,i7 a digital image derived from a glass slide2 7,,ii7 flow cytometry plots2 7,,iii7 cytogenetic karyograms2 7,,iv7 chromatographic1 mass spectrometric1 clinical chemistry1 immunological1 hematological and microbiological data2 7,v7 electropherograms2 7,,vi7 gel images2 7,,vii7 genetic expression1 array and sequencing data2 and 7,,viii7 subsequent analyses of such data2 and 7ii7 is patient-specific when it is accompanied by information that can be used to identify the individual from whose specimen the information was derived4 7,f7 ,investigational use ,the term investigational use means1 with respect to a laboratory developed test1 that the test is used in a clinical investigation1 at least #a purpose of which is to gather data to establish the clinical validity of the test4 7,g7 ,laboratory2 clinical laboratory ,the term laboratory or clinical laboratory means a facility for the examination of materials taken or derived from the human body1 including analysis of patient-specific digital laboratory data1 for clinical use or investigational use4 7,h7 ,laboratory developed test ,the term laboratory developed test-- 7i7 means an examination or procedure1 including an examination or procedure that modifies an in vitro diagnostic device regulated under the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cja et seq471 that is-- 7,i7 developed in a clinical laboratory certified under this section to perform tests of high-complexity2 and 7,,ii7 performed only within-- 7aa7 the same clinical laboratory in which it was developed2 or 7bb7 another clinical laboratory certified under this section to perform tests of high-complexity that is within-- 7,,aa7 the same corporate organization and has common ownership by the same parent corporation as the developing laboratory2 or 7,,bb7 a public health laboratory network coordinated or managed by the ,centers for ,disease ,control and ,prevention or other ,federal public health agency1 if the developing laboratory is a public health laboratory or a laboratory managed by the ,centers for ,disease ,control and ,prevention or other ,federal public health agency2 7ii7 does not include a protocol for an examination or procedure that is commercially distributed for performance in laboratories not under common ownership by the same parent corporation as the laboratory that developed the protocol2 7iii7 is not a medical device subject to regulation under the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cja et seq471 even if the laboratory developed test-- 7,i7 modifies the use of a device that is lawfully marketed under the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cja et seq472 7,,ii7 requires preparation or modification within the laboratory of equipment1 reagents1 instruments1 software1 or other materials for use within the laboratory2 7,,iii7 includes processes1 materials1 research1 or intellectual property developed by third parties if the developing laboratory remains responsible for compliance with applicable requirements for laboratory developed tests under this section2 or 7,,iv7 examines a specimen that was self-collected by an individual1 regardless of the setting in which the specimen was collected2 and 7iv7 is performed in a laboratory described in clause 7i77,,ii7 even if software used in the test is executed outside of the laboratory4 7,i7 ,laboratory operations ,the term laboratory operations-- 7i7 means the conduct of examinations and other procedures on material taken or derived from the human body and associated activities1 including analysis of patient-specific digital laboratory data1 for a purpose described in subparagraph 7,e71 including the development and performance of laboratory developed tests2 and 7ii7 includes-- 7,i7 the preparation and transfer of equipment1 reagents1 instruments1 software1 or other materials between laboratories that are under common ownership by the same parent corporation2 and 7,,ii7 the distribution of specimen collection kits for use with laboratory developed tests if the components of such specimen collection kits are intended to be used consistent with the established intended uses for which they may otherwise be lawfully distributed4 7,j7 ,performance specifications ,the term performance specification means a value or range of values for a characteristic of an examination or procedure1 such as accuracy1 precision1 analytical sensitivity1 analytical specificity1 reportable range1 or other characteristic required for test performance4 7,k7 ,research use ,the term research use means1 with respect to a laboratory developed test1 that the test's purpose is solely for analytical development or scientific research1 and not for use in making clinical decisions for individual patients4 2 7#b7 by adding at the end3 7r7 ,laboratory developed tests 7#a7 ,reasonable assurance of analytical and clinical validity of laboratory developed tests 7,a7 ,standard ,beginning #b years after enactment of the ,enhancing ,,clia ,act of #bjbf1 no laboratory may perform a laboratory developed test unless the test meets the applicable standard4 7,b7 ,analytical validity ,for purposes of meeting the applicable standard under this section1 a laboratory developed test has a reasonable assurance of analytical validity if-- 7i7 the laboratory that develops the test establishes performance specifications that support the ability of the test to identify1 measure1 detect1 calculate1 or analyze #a or more analytes1 biomarkers1 substances1 or other targets intended to be identified1 measured1 detected1 calculated1 or analyzed by the test2 and 7ii7 the laboratory that performs the test1 if different than the laboratory that develops the test1 verifies such performance specifications prior to use4 7,c7 ,clinical validity ,for purposes of meeting the applicable standard under this section1 a laboratory developed test has a reasonable assurance of clinical validity if the laboratory that develops the test has documented evidence1 which may include #a or more of the following that supports the ability of the laboratory developed test to reliably and accurately achieve its stated purpose-- 7i7 peer-reviewed literature2 7ii7 clinical guidelines2 7iii7 bench studies2 7iv7 case studies or histories2 7v7 consensus standards2 7vi7 reference standards2 7vii7 data registries2 7viii7 postmarket data2 7ix7 real world data2 7x7 #a or more clinical validation studies2 or 7xi7 other evidence deemed appropriate by the ,secretary4 7,d7 ,supplemental affirmation that standard has been met 7i7 ,at any time1 a laboratory may1 but is not required to1 obtain #a or more supplemental affirmations that the laboratory developed test meets the applicable standard from a third party approved under subparagraph 7,e71 pursuant to the process in subparagraph 7,f74 ,subject to clause 7ii7 of this subparagraph1 such supplemental affirmation does not expire4 7ii7 ,if a third party approved under subparagraph 7,e7 has its approval withdrawn by the ,secretary1 a supplemental affirmation that a laboratory developed test meets the applicable standard issued by that third party shall remain in effect for no longer than the later of-- 7,i7 #ij days after the date that a third party notifies a laboratory under subparagraph 7,e77iv7 that its approval has been withdrawn2 or 7,,ii7 if within #fj days of receiving the notification under subparagraph 7,e77iv7 the laboratory submits information to a different third party requesting a supplemental affirmation that the laboratory developed test meets the applicable standard1 the date on which such approved third party determines whether the laboratory developed test meets the applicable standard under subparagraph 7,f77i77,,ii74 7,e7 ,approved third parties ,beginning #b years after enactment of the ,enhancing ,,clia ,act of #bjbf1 the ,secretary shall approve third parties to provide a supplemental affirmation that a laboratory developed test meets the applicable standard if-- 7i7 the standards and procedures applied by the third party in determining whether the laboratory developed test meets the applicable standard are determined by the ,secretary to be sufficiently risk-based1 rigorous1 and not overly burdensome2 7ii7 in the case that the third party determines under subparagraph 7,f77ii77,,iii77cc7 that the data and information provided by the laboratory demonstrates that the laboratory developed test does not meet the applicable standard1 the laboratory developed test is being offered with false or deceptive claims1 or that it is probable that the test will cause serious adverse health consequences1 the third party agrees to notify the ,secretary within #aj days of such determination unless the laboratory stops offering1 and notifies the third party that it no longer offers1 the laboratory developed test2 7iii7 the third party agrees to notify the ,secretary at least #cj days before it changes its standards and procedures for determining that a laboratory developed test meets the applicable standard2 and 7iv7 if the third party has its approval withdrawn by the ,secretary1 the third party agrees to notify each laboratory that obtained a supplemental affirmation that the applicable standard was met for any laboratory developed test of the withdrawal within #aj days of the withdrawal4 7,f7 ,process for supplemental affirmation by approved third party 7i7 ,if a laboratory submits information to a third party approved by the ,secretary under subparagraph 7,e7 requesting a supplemental affirmation that a laboratory developed test meets the applicable standard1 the approved third party shall within #fj calendar days of receipt of the submitted information-- 7,i7 review the submitted information1 which may include communication with the laboratory2 and 7,,ii7 determine whether the laboratory developed test meets the applicable standard and communicate such determination with the laboratory as described in clause 7ii74 7ii7 ,the approved third party shall provide written notice to the laboratory of the approved third party's determination under clause 7i77,,ii7 as follows3 7,i7 ,the approved third party shall notify the laboratory if the approved third party determines that the laboratory developed test-- 7aa7 meets the applicable standard2 or 7bb7 does not meet the applicable standard and subclauses 7,,ii7 and 7,,iii7 do not apply4 7,,ii7 ,if the approved third party determines that the laboratory developed test does not meet the applicable standard but that such determination may be resolved within a reasonable time-- 7aa7 the approved third party shall notify the laboratory of such determination and the reasons therefore1 and allow the laboratory to seek a teleconference to discuss the finding2 7bb7 the laboratory shall submit information demonstrating resolution of the determination within #fj days of receiving such notification2 and 7cc7 the approved third party shall make a determination within #cj days of the receipt of such submission of information as to whether the laboratory developed test continues not to meet the applicable standard4 7,,iii7 ,if the approved third party determines that there is a lack of credible and verifiable information supporting that the laboratory developed test meets the applicable standard1 the laboratory developed test is being offered with false or deceptive claims1 or that it is probable that the test will cause serious adverse health consequences-- 7aa7 the approved third party shall notify the laboratory of such determination and the reasons therefore1 and allow the laboratory to seek a teleconference to discuss the finding2 7bb7 the laboratory shall submit information demonstrating resolution of the determination within #fj days of receiving such notification2 and 7cc7 the approved third party shall make a determination within #cj days of the receipt of such submission of information as to whether such determination continues to apply4 7iii7 ,in the case that the third party determines under subparagraph 7,f77ii77,i77bb7 that a laboratory developed test does not meet the applicable standard1 the laboratory may resubmit a request for supplemental affirmation by the same or different third party for review without prejudice at any time4 7iv7 ,in the case that the third party determines under subparagraph 7,f77ii77,,iii77cc7 that there is a lack of credible and verifiable information supporting the analytical or clinical validity of the laboratory developed test1 the laboratory developed test is being offered with false or deceptive claims1 or that it is probable that the test will cause serious adverse health consequences-- 7,i7 the third party will not notify the ,secretary of such determination if the laboratory stops performing such laboratory developed test1 and notifies the third party that it has stopped performing such laboratory test1 within #aj days2 and 7,,ii7 the laboratory may resubmit a request for supplemental affirmation by the same or different third party for review without prejudice at any time4 7,g7 ,deemed supplemental affirmation ,a laboratory developed test shall be deemed to have obtained a supplemental affirmation that it meets the applicable standard under subparagraph 7,d7 if it is-- 7i7 approved by the ,new ,york ,state ,department of ,health2 7ii7 determined to be reasonable and necessary under ,medicare pursuant to a favorable review of a technical assessment under the ,mol,d,x ,program2 7iii7 within a category of tests identified by the ,secretary in regulation that shall be deemed to have obtained a supplemental approval4 7,h7 ,food and drug administration an approved third party 7i7 ,the ,food and ,drug ,administration shall be deemed an approved third party under subparagraph 7,e74 7ii7 ,beginning #b years after enactment of the ,enhancing ,,clia ,act of #bjbf1 a laboratory may request a supplemental affirmation from the ,food and ,drug ,administration that a laboratory developed test for clinical use meets the applicable standard4 7iii7 ,any laboratory seeking supplemental affirmation from the ,food and ,drug ,administration under clause 7ii7 shall pay a fee for such review that is no greater than the applicable user fee for a premarket notification submission under section #gch of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cgi;j74 7iv7 ,if a laboratory seeks supplemental affirmation from the ,food and ,drug ,administration under clause 7ii7 and pays the fee under clause 7iii71 the ,food and ,drug ,administration-- 7,i7 shall review the information for the laboratory developed test only in accordance with the standards applied by the ,secretary under subparagraph 7,a7 and the procedure applied by approved third parties under subparagraph 7,f72 and 7,,ii7 shall not apply to the laboratory developed test the standards or other requirements that apply to devices or any other product regulated under the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cja et seq474 7#b7 ,centralized database for laboratory developed tests for clinical use ,beginning #b years after enactment of the ,enhancing ,,clia ,act of #bjbf1 each laboratory performing #a or more laboratory developed tests for clinical use shall submit to the ,secretary the information described in subparagraph 7,a7 in accordance with the applicable schedule described in subparagraph 7,b74 ,such information shall be submitted electronically to the centralized database established by the ,secretary under subparagraph 7,c74 ,if multiple laboratories within the same corporate organization and with common ownership by the same parent corporation perform the same laboratory developed test1 a corporate entity with common ownership of such laboratories may submit the information described in subparagraph 7,a7 on behalf of such laboratories1 provided that each laboratory performing a laboratory developed test is separately identified with respect to each laboratory developed test it performs4 7,a7 ,submission ,for each laboratory developed test performed for clinical use by the laboratory1 the laboratory shall submit the following information1 as applicable3 7i7 ,name and certificate number of the laboratory4 7ii7 ,name and certificate number of the laboratory that developed the laboratory developed test1 if different than the laboratory performing the laboratory developed test4 7iii7 ,name of the laboratory developed test4 7iv7 ,purpose of the laboratory developed test1 including-- 7,i7 analyte7s7 measured2 7,,ii7 disease7s71 impairment7s7 or assessment7s7 of the health of human beings for which the laboratory developed test is used2 and 7,,iii7 for what purpose7s7 the information from the laboratory developed test will be used1 such as for the screening1 diagnosis1 prognosis1 or other type of assessment4 7v7 ,specimen type7s7 used with the laboratory developed test1 which may include digital laboratory data4 7vi7 ,type of examination1 such as biological1 microbiological1 serological1 chemical1 immuno-hematological1 hematological1 biophysical1 cytological1 pathological1 flow cytometric1 molecular1 genomic1 or other type of examination4 7vii7 ,summary of performance specifications for the laboratory developed test4 7viii7 ,whether the laboratory developed test modifies the use of a device that is lawfully marketed under the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cja et seq47 and1 if applicable1 information identifying the specific device that is modified4 7ix7 ,whether the test is deemed to have a supplemental affirmation under regulations issued by the ,secretary or an approved third party has supplementally affirmed that the laboratory developed test meets the applicable standard and1 if the latter1 the name of such approved third party4 7x7 ,if the laboratory developed test is first performed for clinical use by the laboratory #b or more years after enactment of the ,enhancing ,,clia ,act of #bjbf1 is not deemed to have a supplemental affirmation under regulations issued by the ,secretary1 and an approved third party has not supplementally affirmed that the test meets the applicable standard1 a brief summary of the information in paragraph 7#a77;,b77c7 that supports that the laboratory developed test has a reasonable assurance of clinical validity4 7,b7 ,submission schedule 7i7 ,tests offered #b or more years after enactment of the ,enhancing ,,clia ,act of #bjbf ,if the laboratory developed test is first performed for clinical use by the laboratory #b or more years after the date of enactment of the ,enhancing ,,clia ,act of #bjbf1 the laboratory must submit the information in subparagraph 7,a7 for the laboratory developed test by the later of-- 7,i7 #cj days after such laboratory developed test is first performed for clinical use2 or 7,,ii7 #fj days after the centralized database described in subparagraph 7,c7 is established4 7ii7 ,tests offered prior to the date that is #b years after enactment of the ,enhancing ,,clia ,act of #bjbf ,if the laboratory developed test is first performed for clinical use by the laboratory prior to the date that is #b years after enactment of the ,enhancing ,,clia ,act of #bjbf1 the laboratory must submit the information in subparagraph 7,a7 for the laboratory developed test by the later of-- 7,i7 #c years after enactment of the ,enhancing ,,clia ,act of #bjbf2 or 7,,ii7 #fj days after the centralized database described in subparagraph 7,c7 is established4 7,c7 ,establishment of centralized database ,not later than #b years after enactment of the ,enhancing ,,clia ,act of #bjbf1 the ,secretary shall make available a centralized database that is designed to-- 7i7 provide a transparent interface on the website of the ,centers for ,medicare and ,medicaid ,services for stakeholders1 to the extent permitted by applicable laws1 which may include access to-- 7,i7 information submitted by laboratories under subparagraph 7,a72 and 7,,ii7 information about test errors submitted under paragraph 7#c72 and 7ii7 provide a secure portal for electronic submission of information under subparagraph 7,a7 and reports of test errors under paragraph 7#c71 which provides protections from unauthorized disclosure of information1 including of-- 7,i7 trade secret or confidential commercial financial information2 7,,ii7 information that could compromise national security2 and 7,,iii7 identifiable patient data4 7,d7 ,updates and corrections 7i7 ,a laboratory must update or correct the information submitted under this paragraph for a laboratory developed test within #cj days of-- 7,i7 determining that an update or correction is necessary to maintain the accuracy of the previously submitted information2 or 7,,ii7 a request from the ,secretary to make a specific correction1 unless the laboratory demonstrates within #ba days of such request that a correction is not necessary4 7ii7 ,a laboratory may supplement or modify the information submitted under this paragraph for a laboratory developed test when new information becomes available4 7#c7 ,test error reporting 7,a7 ,definitions ,in this section3 7i7 ,serious harm ,the term serious harm means a misdiagnosis or failure to diagnose that results in the absence1 delay1 or discontinuation of critical medical treatment1 or administration of unnecessary medical treatment1 that causes death or serious injury to the patient4 7ii7 ,serious injury ,the term serious injury means an injury that-- 7,i7 is life threatening2 7,,ii7 results in permanent impairment of a body function or permanent damage to a body structure2 or 7,,iii7 necessitates further medical or surgical intervention to preclude permanent impairment of a body function or permanent damage to a body structure4 7,b7 ,submission of individual reports ,beginning #b years after enactment of the ,enhancing ,,clia ,act of #bjbf1 a laboratory shall submit a report not later than #e calendar days after becoming aware of an undetected inaccurate result for a laboratory developed test for clinical use that reasonably suggests-- 7i7 that a laboratory developed test caused serious harm that resulted in death2 or 7ii7 an imminent threat to public health4 7,c7 ,submission of quarterly reports ,beginning #b years after enactment of the ,enhancing ,,clia ,act of #bjbf1 a laboratory shall submit quarterly reports that include any undetected inaccurate results of which the laboratory becomes aware for laboratory developed tests for clinical use that reasonably suggest that the laboratory developed test caused serious harm other than death4 ,such quarterly reports shall be submitted not later than the end of the quarter following the quarter in which the laboratory becomes aware of such undetected inaccurate results4 7,d7 ,report not an admission ,a report submitted by a laboratory under this paragraph and the ,secretary's release of such report or information does not constitute an admission by the laboratory that the laboratory developed test caused or contributed to serious harm4 7#d7 ,review of analytical and clinical validity 7,a7 ,the criteria described in this subparagraph are that a laboratory developed test in clinical use-- 7i7 does not have a supplemental affirmation under paragraph 7#a77;,d7 that the applicable standard is met1 and the test does not meet the applicable standard2 or 7ii7 has a supplemental affirmation under subparagraph 7#a77;,d7 that the applicable standard is met1 and the test-- 7,i7 is represented for a purpose that is not supported by the supplemental affirmation2 and 7,,ii7 does not meet the applicable standard for such purpose4 7,b7 ,beginning #b years after enactment of the ,enhancing ,,clia ,act of #bjbf1 the ,secretary may issue to the developing laboratory of a laboratory developed test a written request for information that-- 7i7 identifies specific scientific concerns1 based on credible and verifiable information1 which indicate that #a or more of the criteria described in subparagraph 7,a7 apply to the laboratory developed test2 and 7ii7 requesting information that would resolve such concern4 7,c7 ,not later than #de days after receiving a request for information under subparagraph 7,b7-- 7i7 the laboratory-- 7,i7 may seek a teleconference prior to the submission of information under subclause 7,,ii7 to discuss the ,secretary's request2 and 7,,ii7 shall submit the information requested pursuant to subparagraph 7,b71 and may include in such submission a request for a teleconference2 and 7ii7 the ,secretary shall-- 7,i7 schedule a teleconference requested under clause 7i77,i72 and 7,,ii7 hold a teleconference if requested within #aj days of the ,secretary's receipt of the information submitted under clause 7i77,,ii74 7,d7 ,upon receiving a submission under subparagraph 7,c71 the ,secretary shall-- 7i7 review the submitted information within #de calendar days of such receipt1 which may include communication with the laboratory2 and 7ii7 determine whether the criteria listed in subparagraph 7,a7 apply to the laboratory developed test and communicate such determination with the laboratory as described in subparagraph 7,e74 7,e7 ,the ,secretary shall provide written notice to the laboratory of the ,secretary's determination under subparagraph 7,d7 as follows3 7i7 ,the ,secretary shall notify the laboratory if the ,secretary determines that the criteria in subparagraph 7,a7-- 7,i7 do not apply to the laboratory developed test2 or 7,,ii7 apply to the laboratory developed test and clause 7ii7 does not apply4 7ii7 ,if the ,secretary determines that the criteria in subparagraph 7,a7 apply to the laboratory developed test but that such determination may be resolved within a reasonable time1 and the laboratory developed test has not previously been subject to this paragraph on the basis of the same or substantially similar concerns identified in the written request issued under subparagraph 7,b7-- 7,i7 the ,secretary shall notify the laboratory of such a determination and allow the laboratory to seek a teleconference to discuss the finding2 7,,ii7 the laboratory shall submit information demonstrating resolution of the determination within #fj days of receiving such notification2 and 7,,iii7 the ,secretary shall make a determination within #cj days of the receipt of such submission of information as to whether the criteria in subparagraph 7,a7 continue to apply to the laboratory developed test4 7,f7 ,if the ,secretary notifies the laboratory under subparagraph 7,e77i77,,ii7 or 7,e77ii77,,iii7 that the criteria in subparagraph 7,a7 apply to the laboratory developed test1 the laboratory must-- 7i7 cease performing the laboratory developed test until the laboratory obtains a confirmation from the ,secretary under subparagraph 7,g7 that the criteria under subparagraph 7,a7 no longer apply to the laboratory developed test2 and 7ii7 instruct all laboratories within the same corporate organization and under common ownership by the same parent corporation to cease performing the laboratory developed test until the developing laboratory obtains the confirmation described in clause 7i74 7,g7 ,the ,secretary shall1 within #cj days of receiving the information described in this subparagraph1 provide a confirmation that the criteria in subparagraph 7,a7 no longer apply to a laboratory developed test that was previously issued a notification under subparagraph 7,f7 if the laboratory that developed the test submits evidence that-- 7i7 it has obtained a supplemental affirmation from an approved third party under paragraph 7#a77;,d7 that the test meets the applicable standard2 and 7ii7 the criteria in subparagraph 7,a7 no longer apply to the test4 7#e7 ,investigational use ,beginning #b years after enactment of the ,enhancing ,,clia ,act of #bjbf1 a laboratory developed test may not be offered for investigational use unless it meets the applicable standard for such use and the test report and all other advertising and promotional materials for the test clearly state1 ,for investigational use only4 ,clinical validity has not yet been established4 2 7#c7 in subsection 7e77#b77;,a77ii7 by adding at the end except that such standards shall not require that laboratory developed tests offered by the laboratory have a supplemental affirmation from any approved third party that the applicable standard has been met12 7#d7 in subsection 7i77#a77;,c7 by inserting or 7r7 after subsection 7d72 and 7#e7 in subsection 7o7 by striking the period and inserting 1 except that the ,secretary may not delegate to the ,food and ,drug ,administration the responsibility or authority for determining whether any laboratory developed test meets the applicable standard under subsection 7r77#d7 of this section4 ,notwithstanding the prior sentence1 the ,food and ,drug ,administration may provide a supplemental affirmation that a laboratory developed test meets the applicable standard pursuant to subsection 7r77#d77;,f744 7b7 ,amendments to the ,federal ,food1 ,drug1 and ,cosmetic ,act ,the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cja et seq47 is amended-- 7#a7 in section #bja7;h77#a7 by striking the period after pursuant to section #ebj7o7 and inserting or laboratory developed tests as defined in the ,enhancing ,,clia ,act of #bjbf4 ,for clarity1 the term device does not include articles intended solely for medical and scientific research using materials derived from the body of man or other animals1 which are not intended for any use described in subparagraphs 7,a7 through 7,c744 7#b7 in section #eja7;f77#a77;,c7 by striking the period at the end and inserting 1 except that this paragraph does not apply to a device that is distributed for use with a laboratory developed test as defined under the ,enhancing ,,clia ,act of #bjbf if the device could otherwise be lawfully distributed under this ,act44 7#c7 in section #ejb7o7 by striking the period at the end and inserting1 except that this subsection does not apply to a device that is distributed for use with a laboratory developed test as defined under the ,enhancing ,,clia ,act of #bjbf if the device could otherwise be lawfully distributed under this ,act44 7c7 ,national coverage determinations for laboratory developed tests ,section #ahfb7l77#a7 of the ,social ,security ,act 7#db ,u4,s4,c4 #aciey7l77#a77 is amended by adding at the end1 ,for purposes of all existing and future national coverage determinations for a clinical laboratory diagnostic test1 a supplemental affirmation from any approved third party that the applicable standard has been met under section #cec of the ,public ,health ,services ,act 7#db ,u4,s4,c4 #bfc;a et seq471 as amended by the ,enhancing ,,clia ,act of #bjbf shall be considered equivalent to an approval or clearance under the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cja et seq4744 7d7 ,companion diagnostics ,if a diagnostic test result is required for the approval of a drug under section #eje of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cee7 or the licensure of a biologic under section #cea of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #bfb71 such test result may be determined by use of a device regulated under the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cja et seq47 or based on a laboratory developed test with a supplemental affirmation from any approved third party under section #cec of the ,public ,health ,services ,act 7#db ,u4,s4,c4 #bfc;a et seq47 as amended by this ,act4 #c4 ,transition 7a7 ,effective date ,except as otherwise provided in this section1 the amendments made by this ,act shall take effect immediately upon enactment4 7b7 ,transition and regulations 7#a7 ,the ,secretary of ,health and ,human ,services 7in this subsection referred to as the ,secretary7 shall take the following actions1 and may expend such funds as the ,secretary determines necessary to ensure an orderly transition-- 7,a7 within #ahj days of enactment1 promulgate proposed regulations required under the amendments made by this ,act2 7,b7 within #b years of enactment1 establish the centralized database for laboratory developed tests under section #cec7r77#b7 of the ,public ,health ,service ,act1 as added by section #b7;a7 of this ,act2 7,c7 within #b years of enactment1 promulgate final regulations to mitigate potential conflict of interest by organizations that provide multiple oversight services under section #cec of the ,public ,health ,services ,act 7#db ,u4,s4,c4 #bfc;a71 including accreditation of laboratories1 proficiency testing1 and supplemental affirmation for laboratory developed tests2 and 7,d7 within #cj days of enactment1 revise the definition of in vitro diagnostic products at section #hji4c of ,title #ba of the ,code of ,federal ,regulations1 effective immediately1 to clarify that such term-- 7i7 does not include laboratory developed tests as defined in subsection 7a7 of section #b of this ,act2 and 7ii7 includes protocols for use in the diagnosis of disease or other conditions1 including a determination of the state of health1 in order to cure1 mitigate1 treat1 or prevent disease or its sequelae when such protocols are-- 7,i7 commercially distributed for performance in laboratories not under common ownership by the same parent corporation as the laboratory that developed the protocol2 or 7,,ii7 commercially distributed by an entity or individual that is not a laboratory2 except that such protocols are not commercially distributed solely because they are published1 including in public or scientific presentations1 or patented4 7#b7 ,applicability of regulations ,notwithstanding the date on which regulations are issued under paragraph 7#a71 no regulations issued pursuant to the amendments made by this ,act shall be implemented or take effect until #b years after enactment1 except as otherwise specified in this section4 7c7 ,conversion 7#a7 ,this subsection applies to a laboratory developed test as defined in subsection 7a7 of section #b of this ,act that has-- 7,a7 a premarket approval under section #eae of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cfj;e71 an approved humanitarian device exemption under section #ebj7m7 of such ,act 7#ba ,u4,s4,c4 #cfj;j7m771 a clearance under section #eaj7k7 of such ,act 7#ba ,u4,s4,c4 #cfj7k771 an authorization under section #eac7;f77#b7 of such ,act 7#ba ,u4,s4,c4 #cgj;c7f77#b771 an investigational device exemption under section #ebj7;g7 of such ,act 7#ba ,u4,s4,c4 #cfj;j7g771 or a licensure under section #cea of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #bfb72 or 7,b7 a premarket approval application under section #eae of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cfj;e71 an application for humanitarian device exemption under section #ebj7m7 of such ,act 7#ba ,u4,s4,c4 #cfj;j7m771 a premarket notification under section #eaj7k7 of such ,act 7#ba ,u4,s4,c4 #cfj7k771 a de novo classification request under section #eac7;f77#b7 of such ,act 7#ba ,u4,s4,c4 #cgj;c7f77#b771 an investigational device exemption under section #ebj7;g7 of such ,act 7#ba ,u4,s4,c4 #cfj;j7g771 or an application for licensure under section #cea of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #bfb7 pending on the date of enactment4 7#b7 ,notwithstanding any other provision of this ,act1 a laboratory developed test under paragraph 7#a7 shall be a device under section #bja7;h77#a7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cba7;h77#a77 until-- 7,a7 if a notification is submitted under paragraph 7#c77;,a71 the date of such notification2 or 7,b7 if a notification is submitted under paragraph 7#c77;,b71 the earlier of-- 7i7 approval1 clearance1 authorization1 exemption1 or licensure of a modification to such test such that it meets the definition of device under section #bja7;h77#a7 of such ,act 7#ba ,u4,s4,c4 #cba7;h77#a772 7ii7 #b years after enactment2 7iii7 the date a subsequent notification is submitted under paragraph 7#c77;,a72 or 7iv7 #fj days after enactment if no notification is submitted under paragraph 7#c74 7#c7 ,for a laboratory developed test under paragraph 7#a71 within #fj days of enactment1 a laboratory may submit to the ,food and ,drug ,administration a notification that the laboratory-- 7,a7 does not intend to modify the test to meet the definition of a device under section #bja7;h77#a7 of the ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cba7;h77#a772 or 7,b7 intends to modify the test to meet the definition of a device under section #bja7;h77#a7 of the ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cba7;h77#a774 7#d7 ,for a laboratory developed test under paragraph 7#a77;,a71 upon the applicable date in paragraph 7#b7 that such test is no longer a device1 such test is deemed to have a supplemental affirmation from the ,food and ,drug ,administration under section #cec7r77#a77;,d7 of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #bfc;a7r77#a77;,d771 as added by section #b7;a7 of this ,act1 that the laboratory developed test meets the applicable standard4 #d4 ,clinical laboratory improvement amendments 7clia7 updates 7a7 ,,clia specialties ,no later than #ahj days after enactment1 the ,secretary shall issue a proposed regulation to establish new types of examinations that may be performed by laboratories under section #cec of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #bfc;a7 consistent with the current state of clinical laboratory science and technology1 including the advancements with respect to molecular diagnostics1 digital pathology1 and next generation sequencing4 ,within #a year of finalizing such regulations1 the ,secretary must evaluate whether additional proficiency testing programs should be approved for these new specialties under section #cec7;f77#c77;,c7 of such ,act 7#db ,u4,s4,c4 #bfc;a7f77#c77;,c774 7b7 ,notice of subregulatory changes ,if the ,centers for ,medicare and ,medicaid ,services intend to issue new or revised sub-regulatory guidance and policies related to the regulation of laboratories under section #cec of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #bfc;a71 including new or revised ,state operations manuals applicable to the regulation of laboratories1 it must describe such proposed action in a public report at least #ij days prior to taking such action and allow an opportunity for public comment4 7c7 ,engagement with laboratories ,the ,centers for ,medicare and ,medicaid ,services must hold regular open door forums with clinical laboratories1 no less frequently than annually1 to discuss issues related to the regulation of laboratories under section #cec of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #bfc;a74 7d7 ,regulation updates ,at least once every #e years1 the ,centers for ,medicare and ,medicaid ,services must review the regulations promulgated under section #cec of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #bfc;a71 and-- 7#a7 issue a request for information in the ,federal ,register regarding whether updates to such regulations are necessary to reflect advancements in laboratory science and technology2 and 7#b7 establish a public docket1 to remain open for no less than #ahj days1 to solicit public comments on the request for information issued under paragraph 7#a74